{"disease":{"id":"carcinoma-hepatocellular","name":"carcinoma hepatocellular"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03588442","title":"Prospective Surveillance for Very Early Hepatocellular Carcinoma","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT03517332","title":"Circulating Tumor DNA Exposure in Peripheral Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Quantgene Inc.","has_results":false},{"nct_id":"NCT06084234","title":"National Liver Cancer Screening Trial","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":5500,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT05486572","title":"Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI","phase":"NA","overall_status":"RECRUITING","enrollment_count":4700,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT07368530","title":"Using Machine Learning to Identify Responders to TACE or HAIC for uHCC","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT03756051","title":"Harms of Hepatocellular Carcinoma Surveillance","phase":"","overall_status":"COMPLETED","enrollment_count":2871,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT02582918","title":"Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5","phase":"NA","overall_status":"COMPLETED","enrollment_count":2871,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT03782207","title":"A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2756,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03628651","title":"Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":2150,"lead_sponsor_name":"Exact Sciences Corporation","has_results":false},{"nct_id":"NCT07298577","title":"Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Siriraj Hospital","has_results":false},{"nct_id":"NCT06233708","title":"Association Between Pre-op Non-Selective Beta-Blockers and Hepatocellular Carcinoma Recurrence Post-Liver Transplant","phase":"","overall_status":"COMPLETED","enrollment_count":2092,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT00913757","title":"A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area","phase":"","overall_status":"COMPLETED","enrollment_count":1871,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06156748","title":"CT Imaging for Guiding PA-TACE for HCC","phase":"","overall_status":"COMPLETED","enrollment_count":1770,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT03232593","title":"A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)","phase":"","overall_status":"COMPLETED","enrollment_count":1758,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01933945","title":"Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib","phase":"","overall_status":"COMPLETED","enrollment_count":1676,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT01798173","title":"Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":1246,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT00692770","title":"Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1114,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT05352204","title":"Effect of Tumor Micronecrosis on Postoperative Transcatheter Arterial Chemoembolization in Patients With Hepatocellular Carcinomas","phase":"","overall_status":"COMPLETED","enrollment_count":900,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07223424","title":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"Diwakar Davar","has_results":false},{"nct_id":"NCT03713593","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":794,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03878550","title":"Case-Control Study of the Glycotest™ HCC Panel Vs AFP for the Detection of Early-stage Hepatocellular Carcinoma","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":766,"lead_sponsor_name":"Glycotest, Inc.","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT00901901","title":"Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":732,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT05208762","title":"A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":714,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT03663114","title":"A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":713,"lead_sponsor_name":"Eisai Inc.","has_results":false},{"nct_id":"NCT07141056","title":"The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"Guilin Medical University, China","has_results":false},{"nct_id":"NCT04102098","title":"A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":668,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT05225207","title":"A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants","phase":"","overall_status":"COMPLETED","enrollment_count":658,"lead_sponsor_name":"Eisai Korea Inc.","has_results":false},{"nct_id":"NCT05078047","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":646,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT05007106","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":613,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT01774344","title":"Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":573,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT03434379","title":"A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":558,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT03533582","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":537,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04792463","title":"Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Mohamed Abdel-Rahman","has_results":false},{"nct_id":"NCT05383066","title":"Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":490,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT04246177","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":479,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03062358","title":"Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":453,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03017326","title":"Paediatric Hepatic International Tumour Trial","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT06384950","title":"Evaluating the Role of ChatGPT in Educating Patients With Early-stage Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Taipei Veterans General Hospital, Taiwan","has_results":false},{"nct_id":"NCT05429866","title":"Immunological Variables Associated to ICI Toxicity in Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":441,"lead_sponsor_name":"Jules Bordet Institute","has_results":false},{"nct_id":"NCT04576572","title":"Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":424,"lead_sponsor_name":"Inonu University","has_results":false},{"nct_id":"NCT04008082","title":"A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":412,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT07495735","title":"Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":400,"lead_sponsor_name":"First Affiliated Hospital of Wenzhou Medical University","has_results":false},{"nct_id":"NCT02329860","title":"Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":true},{"nct_id":"NCT06427941","title":"A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"BeOne Medicines","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}